Key points from article :
A regenerative medicine company, VascVersa is developing a cell therapy product that has raised over £500,000 from investors.
The first target is “chronic non-healing wounds” which include diabetic foot ulcers.
The firm said it would accelerate the development of Angicyte, which helps the healing process by making new blood vessels, leading to an improved blood supply.
Chief executive Christina O’Neill said: “This investment is a significant milestone for VascVersa."
Aidan Courtney, the chairman, added: “We have received tremendous support from our investors and Queen’s University Belfast which will allow the company to develop new products based on its groundbreaking technology.”
VascVersa is coordinating research in centres in Belfast, London to develop its new cell therapy.
